Developing Conditionally Active Antibodies: Interview with John K. Celebi, President & CEO, Sensei Bio.

In this episode, Ayesha spoke with John K. Celebi, MBA, President & Chief Executive Officer, Sensei Bio, a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Sensei Biotherapeutics specializes in creating conditionally active antibodies. These are engineered to operate specifically within the tumor microenvironment, enhancing the immune system's ability to combat cancer. John Celebi, MBA, has over 25 years of experience building innovative entrepreneurial biotechnology companies. Mr. Celebi currently serves on the Board of Directors of Egle Therapeutics SAS, a biotechnology company developing first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. Mr. Celebi received an MBA from Carnegie Mellon University and a BS in biophysics from the University of California, San Diego. Tune into the episode to learn more about Sensei Bio’s mission and therapeutic approach.    For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured